{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:38:22Z","timestamp":1773761902521,"version":"3.50.1"},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutische Umschau"],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:p> Es gibt substantielle Hinweise, welche die Behauptung, die Serumharns\u00e4ure sei ein wichtiger, unabh\u00e4ngiger Risikofaktor f\u00fcr kardiovaskul\u00e4re Erkrankungen, st\u00fctzen. Dies gilt besonders f\u00fcr Patienten mit arterieller Hypertonie, Herzinsuffizienz oder Diabetes mellitus. Verglichen mit Patienten mit normaler Serumharns\u00e4ure sind erh\u00f6hte Serumharns\u00e4urewerte bei hypertensiven Patienten mit einem drei- bis f\u00fcnffach erh\u00f6htem Risiko f\u00fcr koronare Herzkrankheit oder zerebrovaskul\u00e4re Erkrankung assoziiert. Zusammen mit anderen Risikofaktoren wie \u00dcbergewicht, Hyperlipid\u00e4mie und Hyperglyk\u00e4mie sollte die Harns\u00e4ure in der Risikobeurteilung kardiovaskul\u00e4rer Erkrankungen mitber\u00fccksichtigt werden. Ob eine Reduktion erh\u00f6hter Serumharns\u00e4urewerte den kardiovaskul\u00e4ren Outcome reversibel beeinflusst, muss noch gezeigt werden. Die neuesten Daten der Losartan Intervention for Endpoint Reduction (LIFE) Studie bei Patienten mit Hypertonie und linksventrikul\u00e4rer Hypertrophie zeigen, wie eine medikament\u00f6s bedingte Reduktion der Serumharns\u00e4ure zu unterschiedlichem kardiovaskul\u00e4rem Outcome beitragen kann. <\/jats:p>","DOI":"10.1024\/0040-5930.61.9.547","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T12:23:50Z","timestamp":1138710230000},"page":"547-552","source":"Crossref","is-referenced-by-count":10,"title":["Harns\u00e4ure, ein kardiovaskul\u00e4rer Risikofaktor?"],"prefix":"10.1024","volume":"61","author":[{"family":"Alderman","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Redfern","sequence":"additional","affiliation":[{"name":"Formerly Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, currently Consultant, Goshen, NY 10924"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","container-title":["Therapeutische Umschau"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/0040-5930.61.9.547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T10:38:04Z","timestamp":1652006284000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/0040-5930.61.9.547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9,1]]}},"alternative-id":["10.1024\/0040-5930.61.9.547"],"URL":"https:\/\/doi.org\/10.1024\/0040-5930.61.9.547","relation":{},"ISSN":["0040-5930","1664-2864"],"issn-type":[{"value":"0040-5930","type":"print"},{"value":"1664-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,1]]}}}